HK1068282A1 - Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease - Google Patents

Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease

Info

Publication number
HK1068282A1
HK1068282A1 HK05100633A HK05100633A HK1068282A1 HK 1068282 A1 HK1068282 A1 HK 1068282A1 HK 05100633 A HK05100633 A HK 05100633A HK 05100633 A HK05100633 A HK 05100633A HK 1068282 A1 HK1068282 A1 HK 1068282A1
Authority
HK
Hong Kong
Prior art keywords
crohn
treatment
pharmaceutical composition
ulcerative colitis
sease
Prior art date
Application number
HK05100633A
Other languages
English (en)
Inventor
Kluever Jepsen Svenn
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HK1068282A1 publication Critical patent/HK1068282A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
HK05100633A 2001-10-15 2005-01-24 Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease HK1068282A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2001/000677 WO2003032952A1 (en) 2001-10-15 2001-10-15 Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease

Publications (1)

Publication Number Publication Date
HK1068282A1 true HK1068282A1 (en) 2005-04-29

Family

ID=8149447

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100633A HK1068282A1 (en) 2001-10-15 2005-01-24 Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease

Country Status (15)

Country Link
EP (1) EP1441700B1 (xx)
JP (1) JP4726414B2 (xx)
KR (1) KR100859358B1 (xx)
CN (1) CN100506234C (xx)
AT (1) ATE371441T1 (xx)
CA (1) CA2462905C (xx)
DE (1) DE60130270T2 (xx)
DK (1) DK1441700T3 (xx)
ES (1) ES2288999T3 (xx)
HK (1) HK1068282A1 (xx)
IL (2) IL161193A0 (xx)
MX (1) MXPA04003506A (xx)
NO (1) NO335042B1 (xx)
PT (1) PT1441700E (xx)
WO (1) WO2003032952A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
EP1470819A1 (en) * 2003-04-23 2004-10-27 Ferring B.V. High drug load mesalazine sachet
JP2007523664A (ja) * 2003-04-23 2007-08-23 フェリング ベスローテン フェンノートシャップ 医薬組成物用サシェ
EP1547601A1 (en) * 2003-12-23 2005-06-29 Ferring B.V. Coating method
MX2007002443A (es) * 2004-09-01 2007-05-04 Procter & Gamble Composiciones que comprenden acido 5-amino-2-hidroxibenzoico y un azucar reductor.
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
EP2340812A1 (en) * 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
CA2810283A1 (en) * 2010-09-10 2012-03-15 Pharmazell Gmbh Process for producing crystalline 5-aminosalicylic acid
WO2013134348A1 (en) * 2012-03-07 2013-09-12 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
EP3154523B1 (en) * 2014-06-16 2018-11-21 Valpharma International S.P.A. Formulation for oral administration containing mesalazine
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
JP2017189121A (ja) * 2016-04-11 2017-10-19 国立大学法人旭川医科大学 抗ＴＮＦα抗体適応疾患の治療における抗ＴＮＦα抗体投与時反応の発症リスクを判定する方法、並びに該判定用オリゴヌクレオチドキット

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
JPH0334928A (ja) * 1989-06-29 1991-02-14 Teikoku Seiyaku Kk 潰瘍性大腸炎およびクローン病治療用経口投与製剤
PL186790B1 (pl) * 1995-12-21 2004-02-27 Ferring Farma Lab Farmaceutyczna kompozycja doustna zawierająca 5-ASA i zastosowanie 5-ASA do jej wytwarzania
IT1303753B1 (it) * 1998-11-13 2001-02-23 Ct Lab Farm Srl Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.

Also Published As

Publication number Publication date
PT1441700E (pt) 2007-10-29
EP1441700A1 (en) 2004-08-04
NO335042B1 (no) 2014-09-01
IL161193A0 (en) 2004-08-31
CA2462905A1 (en) 2003-04-24
NO20042011L (no) 2004-06-30
JP4726414B2 (ja) 2011-07-20
EP1441700B1 (en) 2007-08-29
CA2462905C (en) 2011-04-12
DK1441700T3 (da) 2007-10-08
WO2003032952A1 (en) 2003-04-24
KR100859358B1 (ko) 2008-09-22
JP2005509619A (ja) 2005-04-14
IL161193A (en) 2010-05-31
CN100506234C (zh) 2009-07-01
MXPA04003506A (es) 2004-07-23
KR20040047906A (ko) 2004-06-05
ATE371441T1 (de) 2007-09-15
CN1558752A (zh) 2004-12-29
DE60130270T2 (de) 2008-05-29
DE60130270D1 (de) 2007-10-11
ES2288999T3 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
HK1068282A1 (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease
GB0100758D0 (en) Immunogenic complex method of preparation thereof and pharmaceutical compositions containing the same, useful for disease control
HK1085669A1 (en) Mesalazine controlled release oral pharmaceutical compositions
WO2001085212A3 (en) Drug delivery systems for photodynamic therapy
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
CA2481848A1 (en) Active ingredient particles carrying clopidogrel or a salt thereof, their use and method of preparation
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
TR200200716T2 (tr) Ketiyapin granülleri
PL374325A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
MXPA03006526A (es) Composicion farmaceutica que contiene compuestos de aminoacetonitrilo y su uso para la preparacion de una composicion farmaceutica para el tratamiento de plagas endoparasitarias en animales.
HUP0304085A3 (en) The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
HUP0401773A3 (en) Use of [(2-amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkanacid derivatives for the preparation pharmaceutical compositions usable for treatment of pain
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
WO2001068676A3 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzeimittel
HUP0102987A3 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
IL152751A0 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
DK1275383T3 (da) "Modified release" farmaceutisk komposition, der indeholder Bupropion HCI som aktivt stof
Sadikov et al. Development and introduction of the novel domestic anthelmintic agent albendazole

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20211014